Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imvotamab in moderate to severe rheumatoid arthritis
NCT06087406Phase 1Terminated
- Sponsor
- IGM Biosciences
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Imvotamab with Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Mar 2023; status: terminated.
02
Drugs
imvotamab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06087406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087406.